Search Results

February 2022 "We are proud to announce the success of our IPO! Thank you to our shareholders, both historical and new, for their trust. The €25 million fundraising gives us the means to achieve our ambitions: to become a leading player in the field of brain diseases! #IPO #biotech #innovation #traitements #addiction #cannabis #Trisomie21 #Downsyndrome" Read more at the source #DrGPCR #GPCR #IndustryNews

June 2022 "June 15, 2022 06:30 AM EDT - In 2016, Abbie Celniker was promoted to partner at Third Rock

Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders Aelis

gene therapies for sickle cell disease, including first that uses CRISPR Pier Vincenzo Piazza, CEO of AELIS

Exscientia plc in deal worth up to $674M 2023 Half-Year Financial Results and Exciting Developments at Aelis

presenting at the OBIO 2024 Investment Summit X-rays to AlphaFold: the future structure of drug discovery Aelis

Industry News Addex Therapeutics Reports Full Year 2023 Financial Results And Provides Corporate Update Aelis

Cellular Communication Bowes Biomedical Investigator Takes Aim at Cracking Cellular Communication Code Aelis

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Aelis

Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau INAUGURATION OF AELIS